Patent · US Active

Bacteria engineered to reduce hyperphenylalaninemia

US12409195B2 · kind B2 · utility

0Cited by
21References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 12, 2020
Grant dateSep 9, 2025
Priority date
Expiry dateFeb 2, 2043

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.